Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma

MI Canut1, A Alvarez2, J Nadal3, R Abreu4, JA Abreu5, JS Pulido61Glaucoma Section, 2Barraquer Ophthalmology Centre, 3Retina and Vitreous Unit, Macula Section, Institut Universitari Barraquer, Universidad Autonoma de Barcelona, Barcelona, Spain; 4Retina and Vitreous Unit, University Hospital of La Ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Canut MI, Alvarez A, Nadal J, Abreu R, Abreu JA, Pulido JS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9e35669f77cf48109790a82cd02a9126
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e35669f77cf48109790a82cd02a9126
record_format	dspace
spelling	oai:doaj.org-article:9e35669f77cf48109790a82cd02a91262021-12-02T07:48:02ZAnterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma1177-54671177-5483https://doaj.org/article/9e35669f77cf48109790a82cd02a91262011-05-01T00:00:00Zhttp://www.dovepress.com/anterior-segment-changes-following-intravitreal-bevacizumab-injection--a7515https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483MI Canut1, A Alvarez2, J Nadal3, R Abreu4, JA Abreu5, JS Pulido61Glaucoma Section, 2Barraquer Ophthalmology Centre, 3Retina and Vitreous Unit, Macula Section, Institut Universitari Barraquer, Universidad Autonoma de Barcelona, Barcelona, Spain; 4Retina and Vitreous Unit, University Hospital of La Candelaria, Tenerife 5Glaucoma Section, University Hospital of the Canary Islands, Tenerife, Spain; 6Retina and Vitreous Unit, Ophthalmology Department, Mayo Clinic, Rochester, MN, USABackground: The purpose of this study was to describe anterior segment changes in a prospective, interventional, noncomparative case series of patients with neovascular glaucoma secondary to proliferative diabetic retinopathy treated with intravitreal bevacizumab.Methods: Five consecutive patients with neovascular glaucoma and a refractory, symptomatic elevation of intraocular pressure and pronounced anterior segment congestion received intravitreal bevacizumab 1.25 mg/0.05 mL. Follow-up examinations were performed at 4&ndash;16 weeks by the same specialists, with testing performed at hour 48, week 1, and months 1, 3, and 6 after intravitreal bevacizumab.Results: We observed a significant difference (P = 0.021) between initial and mean neovascularization at three months in all the quadrants. At three months, median intraocular pressure was 19 &plusmn; 5.38 (range 12&ndash;26) mmHg. In three of the five cases, diode laser cyclophotocoagulation was required, and in one case a trabeculectomy was performed. One patient showed complete synechial angle closure 48 hours after treatment which required cyclodestructive procedures to normalize intraocular pressure.Conclusion: Intravitreal bevacizumab achieves complete regression of neovascularization in neovascular glaucoma secondary to proliferative diabetic retinopathy, and this regression is stable when associated with treatment of the underlying disease and should be investigated more thoroughly as an adjunct in the management of neovascular glaucoma.Keywords: rubeosis, neovascular, glaucoma, bevacizumab, Avastin&reg;, intravitreal, angle closure, complicationsCanut MIAlvarez ANadal JAbreu RAbreu JAPulido JSDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 715-719 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Canut MI Alvarez A Nadal J Abreu R Abreu JA Pulido JS Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
description	MI Canut1, A Alvarez2, J Nadal3, R Abreu4, JA Abreu5, JS Pulido61Glaucoma Section, 2Barraquer Ophthalmology Centre, 3Retina and Vitreous Unit, Macula Section, Institut Universitari Barraquer, Universidad Autonoma de Barcelona, Barcelona, Spain; 4Retina and Vitreous Unit, University Hospital of La Candelaria, Tenerife 5Glaucoma Section, University Hospital of the Canary Islands, Tenerife, Spain; 6Retina and Vitreous Unit, Ophthalmology Department, Mayo Clinic, Rochester, MN, USABackground: The purpose of this study was to describe anterior segment changes in a prospective, interventional, noncomparative case series of patients with neovascular glaucoma secondary to proliferative diabetic retinopathy treated with intravitreal bevacizumab.Methods: Five consecutive patients with neovascular glaucoma and a refractory, symptomatic elevation of intraocular pressure and pronounced anterior segment congestion received intravitreal bevacizumab 1.25 mg/0.05 mL. Follow-up examinations were performed at 4&ndash;16 weeks by the same specialists, with testing performed at hour 48, week 1, and months 1, 3, and 6 after intravitreal bevacizumab.Results: We observed a significant difference (P = 0.021) between initial and mean neovascularization at three months in all the quadrants. At three months, median intraocular pressure was 19 &plusmn; 5.38 (range 12&ndash;26) mmHg. In three of the five cases, diode laser cyclophotocoagulation was required, and in one case a trabeculectomy was performed. One patient showed complete synechial angle closure 48 hours after treatment which required cyclodestructive procedures to normalize intraocular pressure.Conclusion: Intravitreal bevacizumab achieves complete regression of neovascularization in neovascular glaucoma secondary to proliferative diabetic retinopathy, and this regression is stable when associated with treatment of the underlying disease and should be investigated more thoroughly as an adjunct in the management of neovascular glaucoma.Keywords: rubeosis, neovascular, glaucoma, bevacizumab, Avastin&reg;, intravitreal, angle closure, complications
format	article
author	Canut MI Alvarez A Nadal J Abreu R Abreu JA Pulido JS
author_facet	Canut MI Alvarez A Nadal J Abreu R Abreu JA Pulido JS
author_sort	Canut MI
title	Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
title_short	Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
title_full	Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
title_fullStr	Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
title_full_unstemmed	Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
title_sort	anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/9e35669f77cf48109790a82cd02a9126
work_keys_str_mv	AT canutmi anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma AT alvareza anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma AT nadalj anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma AT abreur anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma AT abreuja anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma AT pulidojs anteriorsegmentchangesfollowingintravitrealbevacizumabinjectionfortreatmentofneovascularglaucoma
_version_	1718399177636970496

Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma

Ejemplares similares